BioCentury | Jul 31, 2020
Product Development

U.K. locks down access to recombinant protein vaccine via GSK, Sanofi deal, its fifth for COVID-19

As the U.K. pushes to secure access to several mechanistically diverse vaccines, the country’s procurement deal with GSK and Sanofi on Wednesday checks the recombinant protein vaccine box. The product has yet to enter the...
BioCentury | Jul 31, 2020
Product Development

Non-human primate data shed light on correlates of protection and duration of immunity to COVID-19 vaccines

Two more COVID vaccine developers have published non-human primate data suggesting efficacy, bringing the total to five. One of the new papers builds on the case for neutralizing antibodies as key correlates of protection; the...
BioCentury | Jul 22, 2020
Product Development

Data Byte: comparing clinical data from five COVID-19 vaccines

Five groups have reported early-stage COVID-19 vaccine data in humans and the findings suggest all of the vaccines may require two doses to induce high neutralizing antibodies and T cell responses, which could make it...
BioCentury | Jul 21, 2020
Product Development

Vaccine hopes, the shifting biopharma workplace & Blueprint’s Dx deal: a BioCentury Podcast

New data for the vaccine candidate from Oxford and AstraZeneca have stoked enthusiasm that countermeasures against COVID-19 are within reach. On the latest edition of the BioCentury This Week podcast , BioCentury editors discuss the latest...
BioCentury | Jul 21, 2020
Product Development

Pfizer, J&J, Merck and Moderna to testify on COVID-19 vaccine status

In testimony prepared for a congressional hearing Tuesday, Pfizer reiterated its goal of submitting a request to FDA for emergency use of a COVID-19 vaccine candidate “as early as October,” and AstraZeneca expressed hope that...
BioCentury | Jul 21, 2020
Product Development

Two-dose schedule, infection levels may shift timelines for AZ-Oxford vaccine

AstraZeneca and Oxford will likely move forward with a two-dose schedule for their adenoviral vaccine following an anticipated Phase I/II readout, a decision that could shift timelines, availability and tolerability of one of the COVID-19...
BioCentury | Jul 21, 2020
Product Development

As U.K. secures access to two more vaccines, task force Chair Bingham says more to come

U.K. Vaccine Taskforce Chair Kate Bingham says supply agreements for U.K. access to COVID-19 vaccines from Valneva and partners BioNTech and Pfizer and are the first of up to eight vaccine deals expected in the...
BioCentury | Jul 8, 2020
Product Development

NIH, Warp Speed streamline preventive mAb, vaccine testing via clinical trial network

On the back of its first COVID-19 mAb investment, Operation Warp Speed launched a clinical trial network with NIH on Wednesday to streamline testing of the modality in prophylactic settings. The COVID-19 Prevention Trials Network...
BioCentury | Jul 8, 2020
Product Development

Novavax gets another boost with $1.6B contract from Operation Warp Speed

While Novavax has yet to bring a vaccine to market, the company remains on a meteoric trajectory most recently marked by a $1.6 billion contract with BARDA and the DoD for its COVID-19 vaccine. The...
BioCentury | Jul 7, 2020
Politics, Policy & Law

FDA credibility on the line with White House pressure on hydroxychloroquine

Demands from President Donald Trump that FDA issue a second Emergency Use Authorization for the use of hydroxychloroquine to treat COVID-19 test agency chief Stephen Hahn’s commitment to public health again, and pose challenges to...
Items per page:
1 - 10 of 543
BioCentury | Jul 31, 2020
Product Development

U.K. locks down access to recombinant protein vaccine via GSK, Sanofi deal, its fifth for COVID-19

As the U.K. pushes to secure access to several mechanistically diverse vaccines, the country’s procurement deal with GSK and Sanofi on Wednesday checks the recombinant protein vaccine box. The product has yet to enter the...
BioCentury | Jul 31, 2020
Product Development

Non-human primate data shed light on correlates of protection and duration of immunity to COVID-19 vaccines

Two more COVID vaccine developers have published non-human primate data suggesting efficacy, bringing the total to five. One of the new papers builds on the case for neutralizing antibodies as key correlates of protection; the...
BioCentury | Jul 22, 2020
Product Development

Data Byte: comparing clinical data from five COVID-19 vaccines

Five groups have reported early-stage COVID-19 vaccine data in humans and the findings suggest all of the vaccines may require two doses to induce high neutralizing antibodies and T cell responses, which could make it...
BioCentury | Jul 21, 2020
Product Development

Vaccine hopes, the shifting biopharma workplace & Blueprint’s Dx deal: a BioCentury Podcast

New data for the vaccine candidate from Oxford and AstraZeneca have stoked enthusiasm that countermeasures against COVID-19 are within reach. On the latest edition of the BioCentury This Week podcast , BioCentury editors discuss the latest...
BioCentury | Jul 21, 2020
Product Development

Pfizer, J&J, Merck and Moderna to testify on COVID-19 vaccine status

In testimony prepared for a congressional hearing Tuesday, Pfizer reiterated its goal of submitting a request to FDA for emergency use of a COVID-19 vaccine candidate “as early as October,” and AstraZeneca expressed hope that...
BioCentury | Jul 21, 2020
Product Development

Two-dose schedule, infection levels may shift timelines for AZ-Oxford vaccine

AstraZeneca and Oxford will likely move forward with a two-dose schedule for their adenoviral vaccine following an anticipated Phase I/II readout, a decision that could shift timelines, availability and tolerability of one of the COVID-19...
BioCentury | Jul 21, 2020
Product Development

As U.K. secures access to two more vaccines, task force Chair Bingham says more to come

U.K. Vaccine Taskforce Chair Kate Bingham says supply agreements for U.K. access to COVID-19 vaccines from Valneva and partners BioNTech and Pfizer and are the first of up to eight vaccine deals expected in the...
BioCentury | Jul 8, 2020
Product Development

NIH, Warp Speed streamline preventive mAb, vaccine testing via clinical trial network

On the back of its first COVID-19 mAb investment, Operation Warp Speed launched a clinical trial network with NIH on Wednesday to streamline testing of the modality in prophylactic settings. The COVID-19 Prevention Trials Network...
BioCentury | Jul 8, 2020
Product Development

Novavax gets another boost with $1.6B contract from Operation Warp Speed

While Novavax has yet to bring a vaccine to market, the company remains on a meteoric trajectory most recently marked by a $1.6 billion contract with BARDA and the DoD for its COVID-19 vaccine. The...
BioCentury | Jul 7, 2020
Politics, Policy & Law

FDA credibility on the line with White House pressure on hydroxychloroquine

Demands from President Donald Trump that FDA issue a second Emergency Use Authorization for the use of hydroxychloroquine to treat COVID-19 test agency chief Stephen Hahn’s commitment to public health again, and pose challenges to...
Items per page:
1 - 10 of 543